Assembly Biosciences price to sales ratio ASMB

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 5.4×
8-year median: 6.8×
Against its 8-year history: 36th; percentile: 0 is its lowest day, 100 its highest
8-year range: 1.7× to 49.6×
Peer median: 1.5×

Assembly Biosciences' price to sales ratio is 5.4× as of Oct 23, 2026.

That is below its 8-year median of 6.8×, close to the middle of its last 8 years.

Over that time it ranged from 1.7× in Jul 2021 to 49.6× in Jul 2020.

The median for 10 large drugmakers of a similar size is 1.5×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	5.4×	5.1×	14.3×
2025	14.3×	2.3×	16.4×
2024	3.4×	3.4×	3.8×
2023	n/m a value too high to mean anything
2022	n/m a value too high to mean anything
2021	1.8×	1.7×	2.5×
2020	2.4×	1.9×	49.6×
2019	36.5×	14.9×	37.4×

Against its peers

Companies in Drug Manufacturers - General nearest Assembly Biosciences' size, closest first, today.

Company	Price to sales ratio
ASMBAssembly Biosciences	5.4×
ARVNArvinas	1.5×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	0.9×
NATRNatures Sunshine Products	0.4×
ABUSArbutus Biopharma	4.6×
AMPHAmphastar Pharmaceuticals	1.5×
OMEROmeros	n/m
Peer median	1.5×

Where Assembly Biosciences ranks

#84of 157Large drugmakers with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Assembly Biosciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.